Influence of ferrous sulfate on the solubility, partition coefficient, and stability of mycophenolic acid and the ester mycophenolate mofetil

Drug Development and Industrial Pharmacy

Volumn 28, Issue 10, 2002, Pages 1275-1283

  Lidgate, Deborah ^a   Brandl, Michael ^a   Holper, Marites ^a   Abubakari, Allassan ^a   Wu, Xiaoyang ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

Ferrous sulfate; Interaction; Mycophenolate mofetil; Mycophenolic acid

Indexed keywords

FERROUS SULFATE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; DRUG DERIVATIVE; FERROUS ION;

ARTICLE; DRUG CAPSULE; DRUG SOLUBILITY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; PARTITION COEFFICIENT; PH; PHYSICAL CHEMISTRY; TABLET FORMULATION; CHEMISTRY; DRUG INTERACTION; SOLUBILITY; TABLET;

CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; DRUG STABILITY; FERROUS COMPOUNDS; HYDROGEN-ION CONCENTRATION; MYCOPHENOLIC ACID; SOLUBILITY; TABLETS;

EID: 0036445385     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.1081/DDC-120015361     Document Type: Article

References (11)

1. Lee, W.A.; Gu, L.; Miksztal, A.R.; Chu, N.; Leung, K.; Nelson, P.H. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm. Res. 1990, 7(2), 161-166.
2. Sollinger, H.W. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995, 60(3), 225-232.
3. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995, 345, 1321-1325.
4. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996, 61, 1029-1037.
5. Kobashigawa, J.; Miller, L.; Renlund, D.; Mentzer, R.; Alderman, E.; Bourge, R.; Costanzo, M.; Eisen, H.; Dureau, G.; Ratkovec, R.; Hummel, M.; Ipe, D.; Johnson, J.; Keogh, A.; Mamelok, R.; Mancini, D.; Smart, F.; Valantine, H. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998, 66(4), 507-515.
6. Wiesner, R.; Rabkin, J.; Klintmalm, G.; McDiarmid, S.; Langnas, A.; Punch, J.; McMaster, P.; Kalayoglu, M.; Levy, G.; Freeman, R.; Bismuth, H.; Neuhaus, P.; Mamelok, R.; Wang, W. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl. 2001, 7(5), 442-450.
7. Bullingham, R.E.S.; Nicholls, A.J.; Kamm, B.R. Clinical pharmacokinetics of mycophenolate mofetil. Clin. Pharmacokinet. 1998, 34(6), 429-455.
8. Hooijmaaijer, E.; Brandl, M.; Nelson, J.; Lustig, D. Degradation products of mycophenolate mofetil in aqueous solution. Drug Dev. Ind. Pharm. 1999, 25(3), 361-365.
9. Morii, M.; Ueno, K.; Ogawa, A.; Kato, R.; Yoshimura, H.; Wada, K.; Hashimoto, H.; Takada, M.; Tanaka, K.; Nakatani, T.; Shibakawa, M. Impairment of mycophenolate mofetil absorption by iron ion. Clin. Pharmacol. Ther. 2000, 68, 613-616.
10. D'Arcy, P.F.; McElnay, J.C. In Metal Ions in Biological Systems; Sigel, H., Ed.; Marcel Dekker: New York, 1982; 1-35.
11. D'Arcy, P.F.; McElnay, J.C. Drug Interactions in the Gut Involving Metal Ions. Rev. Drug Metab. Drug Interact. 1985, 5(2 & 3), 83-112.